文献速递MDS 与骨髓增殖性肿瘤

芦可替尼对比最佳可用疗法治疗无脾肿大且控制不佳的真性红细胞增多症(RESPONSE-2):一项随机、3b期研究的5年随访

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
PubMed 文献 · Lancet Haematol · 2022-05-18

RESPONSE-2是一项在12个国家48家医院开展的开放标签、随机、3b期研究,纳入对羟基脲不耐受或抵抗的无脾肿大真性红细胞增多症患者149例,随机接受芦可替尼(n=74)或最佳可用疗法(n=75)。5年随访结果显示,芦可替尼组第260周时22%(16/74)患者达到持久血细胞比容控制,中位血细胞比容维持在45%以下,5年总生存率芦可替尼组96% vs 最佳可用疗法组91%。

要点

  • 芦可替尼组第260周持久血细胞比容控制率为22%(95%CI 13-33),中位持续时间未达到(95%CI 144至未达到)。
  • 5年随访期间芦可替尼组中位血细胞比容水平维持在45%以下,74例患者260周内共需放血60次。
  • 5年总生存率芦可替尼组96%(95%CI 87-99)vs 最佳可用疗法组91%(95%CI 80-96)。

核心结论

  • RESPONSE-2研究的5年结果支持将芦可替尼作为无脾肿大且控制不佳的真性红细胞增多症患者的二线首选治疗。

研究设计与样本

  • 开放标签、随机、3b期研究,在亚洲、澳大利亚、欧洲和加拿大的12个国家48家医院或诊所开展。
  • 纳入年龄≥18岁、无脾肿大、对羟基脲不耐受或抵抗、美国东部肿瘤协作组体能状态评分≤2的真性红细胞增多症患者。
  • 149例患者按1:1随机分配至芦可替尼组(n=74)或最佳可用疗法组(n=75),芦可替尼起始剂量为10 mg每日两次口服。
  • 最佳可用疗法组患者在28周主要终点未达到时或28周后至80周期间因无效或不耐受可交叉至芦可替尼;第80周时接受芦可替尼治疗的患者(含交叉患者)可继续治疗至第260周。
  • 研究注册号NCT02038036,于2020年4月7日完成;患者入组时间为2014年3月25日至2015年2月11日。

主要发现

  • 中位随访67个月(IQR 65-70);随机化时最佳可用疗法方案包括羟基脲(n=38)、干扰素或聚乙二醇干扰素(n=9)、哌泊溴烷(n=5)、来那度胺(n=1)或无治疗(n=22)。
  • 第28周至第80周期间,最佳可用疗法组75例中58例(77%)交叉至芦可替尼;按方案第80周后无患者继续最佳可用疗法。
  • 第260周时芦可替尼组74例中16例(22%;95%CI 13-33)达到持久血细胞比容控制,估计中位持续时间未达到(NR;95%CI 144至NR);最佳可用疗法组因第80周时应答者数量少未报告中位持续时间。
  • 5年随访期间芦可替尼组中位血细胞比容水平维持在45%以下;芦可替尼组74例患者260周内共需放血60次,最佳可用疗法组75例患者80周内共需放血106次。
  • 5年总生存率芦可替尼组96%(95%CI 87-99)vs 最佳可用疗法组91%(95%CI 80-96);研究期间无治疗相关死亡。

关键数值与推荐

  • 芦可替尼组(n=74)与最佳可用疗法组(n=75)最常见的3-4级不良事件(暴露调整后每100患者年)为高血压(8例[2.4%] vs 3例[5.6%])、血小板减少(1例[0.3%] vs 3例[5.6%])和血小板增多(0 vs 4例[7.5%])。
  • 任何级别血栓栓塞事件的暴露调整发生率在芦可替尼组为每100人年1.5%(74例中5例),在最佳可用疗法组为每100人年3.7%(75例中2例)。

临床怎么用

  • 5年结果支持将芦可替尼作为无脾肿大且控制不佳的真性红细胞增多症患者的二线首选治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 3b, randomised, open-label RESPONSE-2 study in patients with inadequately controlled polycythaemia vera without splenomegaly showed superiority of the Janus kinase (JAK) 1 and JAK2 inhibitor ruxolitinib versus best available therapy for the primary endpoint of haematocrit control at week 28. Here, we present secondary endpoints of the RESPONSE-2 study after 5 years of follow-up. METHODS: RESPONSE-2 was an open-label, randomised, phase 3b study done at 48 hospitals or clinics across 12 countries in Asia, Australia, Europe, and Canada. Patients (aged ≥18 years) with polycythaemia vera without splenomegaly, who were intolerant of, or resistant to hydroxyurea, with an Eastern Cooperative Oncology Group performance status of 2 or less were randomly assigned (1:1) to receive ruxolitinib or best available therapy for up to 80 weeks. Patients received oral ruxolitinib at a starting dose of 10 mg twice a day or best available therapy. Patients assigned to best available therapy could cross over to ruxolitinib at week 28 if the primary endpoint was not met, or after week 28 and up to week 80 if best available therapy was ineffective or not tolerated. Patients receiving ruxolitinib at week 80, including crossover patients, could continue ruxolitinib treatment up to week 260. We assessed secondary endpoints at week 260, including durable haematocrit control, median duration of haematocrit control, median haematocrit level over time, number of phlebotomies, and overall survival. Analyses were based on the intention-to-treat principle. This study is registered with ClinicalTrials.gov, NCT02038036 and was completed on April 7, 2020. FINDINGS: Patients were enrolled between March 25, 2014 and Feb 11, 2015. 149 patients were randomly assigned to ruxolitinib (n=74) or best available therapy (n=75). The median follow-up was 67 months (IQR 65-70). At randomisation, best available therapy regimens included hydroxyurea (n=38), interferon or pegylated interferon (n=9), pipobroman (n=5), lenalidomide (n=1), or no treatment (n=22). Between weeks 28 and 80, 58 (77%) of 75 patients in the best available therapy group crossed over to ruxolitinib; no patients continued best available therapy after week 80 per protocol. 97 patients received ruxolitinib until week 260, including 59 (80%) of 74 patients in the ruxolitinib group and 38 (66%) of 58 patients in the crossover groups. At week 260, 16 (22%; 95% CI 13-33) of 74 patients in the ruxolitinib group had achieved durable haematocrit control, with estimated median duration not reached (NR; 95% CI 144 to NR). Median duration of haematocrit control was not reported for patients in the best available therapy group due to the small number of responders by week 80. During the 5-year follow-up, median haematocrit level among patients in the ruxolitinib group remained below 45%. 60 phlebotomies were required among 74 patients in the ruxolitinib group in 260 weeks, and 106 phlebotomies among 75 patients in the best available therapy group in 80 weeks. 5-year overall survival was 96% (95% CI 87-99) in the ruxolitinib group and 91% (80-96) in the best available therapy group. The most common grade 3-4 adverse events (exposure-adjusted per 100 patient-years) in the ruxolitinib group (n=74) and best available therapy group (n=75) were hypertension (eight [2·4%] vs three [5·6%]), thrombocytopenia (one [0·3%] vs three [5·6%]), and thrombocytosis (0 vs four [7·5%]). Exposure-adjusted rates of any-grade thromboembolic events were 1·5% per 100 person-years (five of 74 patients) in the ruxolitinib group and 3·7% per 100 person-years (two of 75 patients) in the best available therapy group. No treatment-related deaths occurred during the study. INTERPRETATION: 5-year results from the RESPONSE-2 study support the use of ruxolitinib as a second-line therapy of choice for patients with inadequately controlled polycythaemia vera without splenomegaly. FUNDING: Novartis.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Passamonti F, Palandri F, Saydam G, et al. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematol. 2022. PMID: 35597252. doi:10.1016/S2352-3026(22)00102-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。